Solid growth for PharmAust's chemistry arm

Claremont-based biotech company PharmAust has announced a record year for its synthetic and medicinal chemistry subsidiary, and has flagged further growth in the year ahead.

PharmAust subsidiary, Epichem, generated $3.1 million in revenue for FY17, up 30 per cent on its performance in FY16.

The result was achieved on the back of advancements across each of its business divisions, including its drug discovery services arm, which benefitted from a significant new US-based customer.


(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 7 articles per month + twice daily business email alerts.

Thanks! This question prevents spammers...
Enter the characters shown in the image.

Add your comment

PharmAust (PAA)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Company Documents

BNiQ Disclaimer